About INmune Bio
INmune Bio (NASDAQ:INMB), a biotechnology firm, specializes in developing treatments that modulate the innate immune system to tackle diseases like cancer and Alzheimer's. The company is innovating in two primary areas: immuno-oncology, aiming to reprogram the tumor microenvironment to improve the effectiveness of cancer treatments, and neurodegeneration, designing therapies to decrease neuroinflammation and improve neuronal function for conditions like Alzheimer's disease. INmune Bio's objectives revolve around advancing its clinical programs to bring novel therapies to patients in need, while also exploring the underlying mechanisms of the innate immune response as a pathway to innovative treatments. Their projects range from early-stage research to advanced clinical trials, showcasing a commitment to science-driven solutions for complex health challenges.
Snapshot
Operations
Products and/or services of INmune Bio
- XPro1595, a novel therapeutic targeting inflammation in Alzheimer's disease to protect neuronal cells and improve cognition.
- INB03, an immunotherapy aimed at reducing tumor progression in cancer by modulating the tumor microenvironment.
- Quellor, a treatment designed to suppress cytokine storm in severe cases of COVID-19, potentially reducing mortality.
- INB04, a next-generation immunotherapy targeting multiple inflammatory pathways to treat severe autoimmune diseases.
INmune Bio executive team
- Mr. David J. Moss M.B.A.President, CEO, Treasurer, Secretary & Director
- Dr. Mark William Lowdell Ph.D.Chief Scientific Officer & Chief Manufacturing Officer
- Mr. Cory Randall EllspermannInterim Chief Financial Officer
- Mr. Daniel Frederick CarlsonHead of Investor Relations
- Mr. Joshua S. Schoonover Esq.General Counsel